Frequency and Spectrum of Genomic Integration of Recombinant Adeno-Associated Virus Serotype 8 Vector in Neonatal Mouse Liver

ABSTRACT Neonatal injection of recombinant adeno-associated virus serotype 8 (rAAV8) vectors results in widespread transduction in multiple organs and therefore holds promise in neonatal gene therapy. On the other hand, insertional mutagenesis causing liver cancer has been implicated in rAAV-mediated neonatal gene transfer. Here, to better understand rAAV integration in neonatal livers, we investigated the frequency and spectrum of genomic integration of rAAV8 vectors in the liver following intraperitoneal injection of 2.0 × 1011 vector genomes at birth. This dose was sufficient to transduce a majority of hepatocytes in the neonatal period. In the first approach, we injected mice with a β-galactosidase-expressing vector at birth and quantified rAAV integration events by taking advantage of liver regeneration in a chronic hepatitis animal model and following partial hepatectomy. In the second approach, we performed a new, quantitative rAAV vector genome rescue assay by which we identified rAAV integration sites and quantified integrations. As a result, we find that at least ∼0.05% of hepatocytes contained rAAV integration, while the average copy number of integrated double-stranded vector genome per cell in the liver was ∼0.2, suggesting concatemer integration. Twenty-three of 34 integrations (68%) occurred in genes, but none of them were near the mir-341 locus, the common rAAV integration site found in mouse hepatocellular carcinoma. Thus, rAAV8 vector integration occurs preferentially in genes at a frequency of 1 in approximately 103 hepatocytes when a majority of hepatocytes are once transduced in the neonatal period. Further studies are warranted to elucidate the relationship between vector dose and integration frequency or spectrum.

[1]  Theresa A. Storm,et al.  Large-Scale Molecular Characterization of Adeno-Associated Virus Vector Integration in Mouse Liver , 2005, Journal of Virology.

[2]  M. McBurney,et al.  Evidence for repeat-induced gene silencing in cultured Mammalian cells: inactivation of tandem repeats of transfected genes. , 2002, Experimental cell research.

[3]  Juan Li,et al.  Patterns of gene expression from in utero delivery of adenoviral-associated vector serotype 1. , 2005, Human Gene Therapy.

[4]  C. Elliger,et al.  Enhanced secretion and uptake of beta-glucuronidase improves adeno-associated viral-mediated gene therapy of mucopolysaccharidosis type VII mice. , 2002, Molecular therapy : the journal of the American Society of Gene Therapy.

[5]  Prerna Sharma,et al.  Circular Intermediates of Recombinant Adeno-Associated Virus Have Defined Structural Characteristics Responsible for Long-Term Episomal Persistence in Muscle Tissue , 1998, Journal of Virology.

[6]  B. Byrne,et al.  Sustained correction of glycogen storage disease type II using adeno-associated virus serotype 1 vectors , 2005, Gene Therapy.

[7]  Lili Wang,et al.  Novel adeno-associated viruses from rhesus monkeys as vectors for human gene therapy , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[8]  T. Conlon,et al.  Recombinant Adeno-Associated Virus Serotype 9 Leads to Preferential Cardiac Transduction In Vivo , 2006, Circulation research.

[9]  M. Kay,et al.  Silencing of episomal transgene expression by plasmid bacterial DNA elements in vivo , 2004, Gene Therapy.

[10]  Daniel G. Miller,et al.  AAV Vector Integration Sites in Mouse Hepatocellular Carcinoma , 2007, Science.

[11]  W. Reith,et al.  The Assembly and Maintenance of Heterochromatin Initiated by Transgene Repeats Are Independent of the RNA Interference Pathway in Mammalian Cells , 2006, Molecular and Cellular Biology.

[12]  Theresa A. Storm,et al.  Extrachromosomal Recombinant Adeno-Associated Virus Vector Genomes Are Primarily Responsible for Stable Liver Transduction In Vivo , 2001, Journal of Virology.

[13]  Theresa A. Storm,et al.  Unrestricted Hepatocyte Transduction with Adeno-Associated Virus Serotype 8 Vectors in Mice , 2005, Journal of Virology.

[14]  David Garrick,et al.  Repeat-induced gene silencing in mammals , 1998, Nature Genetics.

[15]  M. Kay,et al.  Free DNA ends are essential for concatemerization of synthetic double-stranded adeno-associated virus vector genomes transfected into mouse hepatocytes in vivo. , 2003, Molecular therapy : the journal of the American Society of Gene Therapy.

[16]  M. Kay,et al.  Isolation of Recombinant Adeno-Associated Virus Vector-Cellular DNA Junctions from Mouse Liver , 1999, Journal of Virology.

[17]  W. W. Nichols,et al.  Plasmid DNA Vaccines: Investigation of Integration into Host Cellular DNA following Intramuscular Injection in Mice , 2001, Intervirology.

[18]  B. Byrne,et al.  Rescue of enzyme deficiency in embryonic diaphragm in a mouse model of metabolic myopathy: Pompe disease , 2004, Development.

[19]  D. Duan,et al.  Efficient whole-body transduction with trans-splicing adeno-associated viral vectors. , 2007, Molecular therapy : the journal of the American Society of Gene Therapy.

[20]  N. Chirmule,et al.  Long‐term transgene expression in cardiac and skeletal muscle following fetal administration of adenoviral or adeno‐associated viral vectors in mice , 2003, The journal of gene medicine.

[21]  Daniel G. Miller,et al.  Large-Scale Analysis of Adeno-Associated Virus Vector Integration Sites in Normal Human Cells , 2005, Journal of Virology.

[22]  Bing Wang,et al.  Adeno-associated virus serotype 8 efficiently delivers genes to muscle and heart , 2005, Nature Biotechnology.

[23]  F. Bushman,et al.  Retroviral DNA Integration: ASLV, HIV, and MLV Show Distinct Target Site Preferences , 2004, PLoS biology.

[24]  Theresa A. Storm,et al.  Increasing the size of rAAV-mediated expression cassettes in vivo by intermolecular joining of two complementary vectors , 2000, Nature Biotechnology.

[25]  Theresa A. Storm,et al.  Helper-independent and AAV-ITR-independent chromosomal integration of double-stranded linear DNA vectors in mice. , 2003, Molecular therapy : the journal of the American Society of Gene Therapy.

[26]  Philip R. Johnson,et al.  Genetic Fate of Recombinant Adeno-Associated Virus Vector Genomes in Muscle , 2003, Journal of Virology.

[27]  S. Hoffman,et al.  Plasmid DNA malaria vaccine: the potential for genomic integration after intramuscular injection. , 1999, Human gene therapy.

[28]  I. Alexander,et al.  Gene delivery to the juvenile mouse liver using AAV2/8 vectors. , 2008, Molecular therapy : the journal of the American Society of Gene Therapy.

[29]  R. Palmiter,et al.  Molecular pathogenesis of hepatocellular carcinoma in hepatitis B virus transgenic mice , 1989, Cell.

[30]  Theresa A. Storm,et al.  DNA Palindromes with a Modest Arm Length of ≳20 Base Pairs Are a Significant Target for Recombinant Adeno-Associated Virus Vector Integration in the Liver, Muscles, and Heart in Mice , 2007, Journal of Virology.

[31]  S. Kung,et al.  Adeno-associated viral vector-mediated gene transfer of human blood coagulation factor IX into mouse liver. , 1998, Blood.

[32]  T. Flotte,et al.  DNA-dependent PK inhibits adeno-associated virus DNA integration , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[33]  D. Duan,et al.  Efficient Whole-body Transduction with Trans-splicing Adeno-associated Viral Vectors. , 2007, Molecular therapy : the journal of the American Society of Gene Therapy.

[34]  M. R. Delgado Alvira,et al.  Clades of Adeno-Associated Viruses Are Widely Disseminated in Human Tissues , 2004, Journal of Virology.

[35]  Theresa A. Storm,et al.  The Role of DNA-PKcs and Artemis in Opening Viral DNA Hairpin Termini in Various Tissues in Mice , 2007, Journal of Virology.

[36]  M. Sands,et al.  Prevention of systemic clinical disease in MPS VII mice following AAV-mediated neonatal gene transfer , 2001, Gene Therapy.

[37]  Theresa A. Storm,et al.  A Limited Number of Transducible Hepatocytes Restricts a Wide-Range Linear Vector Dose Response in Recombinant Adeno-Associated Virus-Mediated Liver Transduction , 2002, Journal of Virology.

[38]  Theresa A. Storm,et al.  Preclinical in vivo evaluation of pseudotyped adeno-associated virus vectors for liver gene therapy. , 2003, Blood.

[39]  Christopher H Contag,et al.  Comparison of gene expression after intraperitoneal delivery of AAV2 or AAV5 in utero. , 2003, Molecular therapy : the journal of the American Society of Gene Therapy.

[40]  R. Samulski,et al.  Integration of adeno-associated virus (AAV) and recombinant AAV vectors. , 2004, Annual review of genetics.

[41]  D. Duan,et al.  Systemic AAV-9 transduction in mice is influenced by animal age but not by the route of administration , 2007, Gene Therapy.

[42]  Cameron S. Osborne,et al.  LMO2-Associated Clonal T Cell Proliferation in Two Patients after Gene Therapy for SCID-X1 , 2003, Science.

[43]  R. Martienssen,et al.  Maintenance of heterochromatin by RNA interference of tandem repeats , 2003, Nature Genetics.

[44]  Daniel G. Miller,et al.  Adeno-associated virus vectors integrate at chromosome breakage sites , 2004, Nature Genetics.

[45]  W. Low,et al.  Correction of metabolic, craniofacial, and neurologic abnormalities in MPS I mice treated at birth with adeno-associated virus vector transducing the human alpha-L-iduronidase gene. , 2004, Molecular therapy : the journal of the American Society of Gene Therapy.

[46]  Theresa A. Storm,et al.  Robust systemic transduction with AAV9 vectors in mice: efficient global cardiac gene transfer superior to that of AAV8. , 2006, Molecular therapy : the journal of the American Society of Gene Therapy.